摘要
为提高原发性肝癌（Ｐｒｉｍａｒｙｈｅｐａｔｉｃａｎｃｅｒ，ＰＨＣ）早期诊断阳性率，通过监测异常凝血酶原（ａｂ－ｎｏｒｍａｌｐｒｏｔｅｉｎｉｎｄｕｃｅｄｂｙｖｉｔａｎｉｎｋａｂｓｅｎｃｅｏｒａｎｔａｇｏｎｉｓｔＰＩＶＫＡ－Ⅱ）水平对ＰＨＣ疗效作一评价。本试验应用酶联免疫法在１８０人中进行ＰＩＶＫＡ－Ⅱ检测。ＰＨＣ７２例，其它肝病５８例（包括肝硬化、慢性肝炎、肝囊肿、肝血管瘤，继发性肝癌）及正常对照５０例。正常组５０例血浆中ＰＩＶＫＡ－Ⅱ全为阴性反应，ＰＨＣ中４７例阳性反应，其它肝病中仅肝硬化、慢性肝炎各为１例呈阳性反应。ＰＨＣ的ＰＩＶＫＡ－Ⅱ检测敏感性６５％，特异性９８％，ＰＩＶＫＡ－Ⅱ和ＡＦＰ无相关性（ｒ＝０．１１）。两种方法联合检测ＰＨＣ阳性率７９％、小肝癌诊断阳性率５７％、经治疗有效者，ＰＩＶＫＡ－Ⅱ浓度下降，无效者水平增高。血浆中的ＰＩＶＫＡ－Ⅱ浓度增高对ＰＨＣ有特异性的诊断意义，两种方法联合检测可提高ＰＨＣ检出率，检测ＰＩＶＫＡ－Ⅱ对ＰＨＣ与各种良性肝病有鉴别意义。
PIVKAII was measured using an EIA in 180 human subjects, of which 72 were patients with PHC and 58 with other liver diseases.The control group consisted of normal individuals. PIVKAII was positive in 47 out of 72 PHC patients(65%), but was nil in the control group. It was positive in only 2 out of 58 patients with other liver diseases (P<0.05). The concentration of PIVKAII in the plasma was not correlated with that of AFP (r=0.11).Combination assay of both markers was positive in 56 out of 72 patients with PHC (79%). In patients with PHC who responded favorably to treatment the concentration of PIVKAII reduced markedly, while in patients in whom no improvement occurred the concentration increased in line with the tumor growth. The positive rate in small PHC was 57%. Therefore, it is of clinical significance if the PIVKAII increased in patients with PHC.Combination of PIVKAII and AFP may enhance the accuracy of diagnosis of PHC.Determination of PIVKAII can not only differentiate PHC from other liver diseases but it also monitors the progression of PHC and the therapeutic effect.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1998年第1期38-40,共3页
Chinese Journal of Clinical Oncology
基金
沈阳市科委科研基金
